About C3 Summit
C3 Summit (Conversations on Clinical Content) is part of a series of events that offers sponsors, CROs, and biotech professionals opportunities to share knowledge, gain industry insights, and network. The series has been celebrated for its casual yet informative format and time-efficient, well curated discussions. Previous panels have featured topics such as inclusivity and diversity in patient recruitment, practical applications of AI/ML, regulatory inspection stories and best practices, clinical outcome assessments, future-proofing clinical operations, among other important topics.
Why Attend C3 Summit?
NETWORKING
Connect with industry peers in the life sciences community, spend time with familiar colleagues, and make new connections.
KNOWLEDGE SHARING
Acquire new approaches by hearing strategies and experiences from peers sharing successes and lessons learned.
PRACTICAL TAKEAWAYS
Return to your teams with pragmatic insights that can be directly applied to existing strategies and processes.
CONVENIENCE
Enjoy a day of efficient, insight-packed panels followed by a happy hour in an experience celebrated for its concise format.
ONE-OF-A-KIND EVENT
Experience the synergy that only one of TransPerfect’s world class events can provide—where every discussion and new connection contributes to an energy that cannot be replicated.
Interested in seeing last year’s panel discussions?
Watch our 2025 C3 Summit London panel topics, which focused on diversity and inclusivity in patient recruitment, clinical outcome assessments, digital health, and more.
Speakers
Agenda
8:30 — 9:30 AM
Check-in
9:30 — 10:00 AM
Opening Remarks
10:00 — 10:45 AM
The Patient Partnership: Reshaping Research and Advocacy
The patient voice panel brings together patient advocates and industry leaders to examine how patient experiences shape healthcare research, access and advocacy, and where the gaps between intention and practice still exist. The discussion covers clinical trial design, therapeutic development and the organizational decisions that determine whether patient input actually changes anything. Speakers will share where collaboration has worked, where it has fallen short and what it takes for the industry to treat patients as partners from the start, not as an audience for decisions already made.

Alexandra Charge is a global life sciences executive specialising in strategic transformation, innovation and patient-centric approaches across healthcare, medicines development and clinical trial optimisation. She brings extensive leadership experience in the pharmaceutical sector and is an active industry voice advancing patient-focused drug development, inclusive research and equitable healthcare. Alexandra has led initiatives in Clinical Innovation, Digital Health, DCT/Hybrid Strategy, and business process transformation to accelerate access to medicines for patients.

Jamie Tierney is the patient-led founder of DMD Pathways, built from his lived experience navigating Duchenne muscular dystrophy for his son. After facing a system where information, access and support were fragmented – and reaching a point where hope and answers felt out of reach – Jamie set out to change that reality for other families. DMD Pathways is designed to bring clarity to a complex global landscape, helping families understand what exists and how to navigate it. His work focuses on improving visibility, expanding access and empowering families earlier in their journey, so no one faces Duchenne without a clear path forward.

Caleigh Haber is a patient advocate, speaker and community strategist focused on improving communication, education and trust in healthcare and clinical research. Living with cystic fibrosis and having undergone two double lung transplants, she brings firsthand experience of navigating complex medical systems. Her work centres on patient experience, digital health communication and research engagement. Caleigh is the founder of Fight2Breathe, an online platform connecting a global community of people living with chronic and rare diseases. She is also involved in initiatives to expand access to healthcare and reliable health information in underserved communities, with a growing interest in how emerging technologies such as AI can make medical knowledge more understandable and accessible to patients worldwide.

Steve Clark is a strategist, business consultant and patient engagement consultant with over 45 years of healthcare experience. He supports strategy development, including process design and the development of strategic and operational plans, as well as key initiatives such as patient and HCP education programmes. Since being diagnosed with stage 4 colorectal cancer in 2013, Steve has become an active patient advocate. In 2017, he founded Strive for Five, a not-for-profit organisation with a mission to give hope to fellow stage 4 cancer patients and advocate for improved care for those with advanced cancer.

Julie Powell is a commercial leader in the pharmaceutical industry with over 13 years of experience across Europe, spanning business development, marketing and market access in specialty and rare diseases. She currently leads global commercial strategy for an oncology biotech and is also building PatientGroups.co, a platform that maps and analyses patient advocacy groups worldwide using a proprietary algorithm. Her work focuses on improving patient engagement, accelerating clinical trial recruitment and enabling more patient-centric drug development. Julie is passionate about bridging the gap between industry and patient communities to drive better outcomes.

Antonio Drea is a Director at TransPerfect Life Sciences, where he specializes in patient recruitment and retention services, as well as commercial strategy for global clinical research initiatives. With extensive experience helping clients accelerate therapy development, Antonio partners with leading healthcare organizations to improve access to life-changing treatments and empower patients through innovative, accessible information solutions.
10:45 — 11:15 AM
Technology-Driven Patient Engagement: Turning Interactions into Better Outcomes
Digital technology is transforming how we engage patients—but are we doing it in a way that’s truly effective, equitable, and meaningful? This session cuts through the AI hype to explore what’s actually working in patient engagement today, from personalization and LLM-powered tools to video content and emerging digital channels. We’ll also tackle the harder questions: who risks being left behind as digital adoption accelerates, and how do compliance and security considerations shape what’s possible? Drawing on real case studies and perspectives from clinical trial recruitment and patient empowerment, we examine how engagement can drive measurable outcomes, with a spotlight on an under-researched shift already underway: patients using AI tools to self-educate and arrive at appointments more informed than ever before.

Dr Monica Hadi is a HEOR and RWE specialist with an MSc in Health Psychology from University College London and a DPhil from the University of Oxford. She has over 40 peer-reviewed publications and more than 17 years of experience in patient-centred research, epidemiology and evidence strategy. She has extensive experience in study design, HTA-ready deliverables and publication planning.

Arthur Silvente has 12 years of experience in the life sciences sector and is passionate about using innovative solutions to solve client challenges. He leads the TransPerfect Digital Life Sciences practice and oversees global strategic relationships with multiple large pharmaceutical companies.
11:15 — 11:45 AM
Promise, Pragmatism and Practical Gains for AI in Drug Discovery and Clinical Outcomes
AI holds real promise but matching that promise to realistic expectations is where the real work begins. In this session, panelists will examine how AI can benefit drug discovery, specifically in terms of speed, HTA cost-effectiveness modelling, disease predictive signaling, leveraging synthetic study arms to reduce patient cohort size, and advancing clinical outcome assessment through richer patient data.


Dr Vivienne Hanrahan is a patient engagement professional with a background in clinical practice and a PhD in Clinical Trial Methodology. She embeds the patient perspective early in drug development and across the product lifecycle, ensuring a consistent and meaningful narrative. Drawing on expertise in qualitative research and behavioural science, she applies rigorous, innovative approaches to capturing and interpreting lived patient experience, focusing on ethical implementation, trust and accessibility. She is particularly interested in how AI is shaping new approaches to capturing and measuring patient experience in health research.

Andrew Lloyd co-founded and led Acaster Lloyd, a research consultancy focused on patient-centred outcomes research. Following the company’s transition to employee ownership, he now acts as a Scientific Advisor. Andrew sits on the Board of the EuroQol Group, which supports the use and development of the EQ-5D and related instruments.

Tom Willgoss is the Immunology Lead in Roche’s Digital Endpoints and Patient-Centred Solutions (DEPCS) team, specialising in generating patient-centred data through clinical outcome assessments, imaging and digital health technologies. He serves on the Board of Directors for the International Society for Quality of Life Research (ISOQOL) and has published extensively on patient-centred outcomes research. Prior to joining Roche in 2016, Tom worked across a range of settings, including consultancy, academia and clinical practice.

Mark P. Wade is Global Practice Leader at TransPerfect Life Sciences, the world’s largest provider of clinical document handling and language translation services. In this role, he serves as a subject matter expert in life sciences processes and translation.
Mark brings more than 20 years of experience in the life sciences industry. His background includes serving as International Regional Director for EMEA at Ethicon and Ethicon Endo-Surgery, both Johnson & Johnson companies (NYSE: JNJ). Prior to joining TransPerfect, he spent nearly a decade as Global Practice Leader at another global language translation company.
A published expert in Electronic Clinical Outcomes Assessments (eCOA), Mark has authored two eBooks, multiple clinical posters, and numerous articles in industry trade journals. His work also spans clinical services, patient recruitment, and site selection.
Mark has chaired sessions, presented, and published posters at DIA, ISOQOL, ISPOR Annual Symposia, and many other internationally recognized conferences. He previously served as Co-Director for Industry at the C-Path eCOA Consortium and currently holds the position of Delegate Member. He is also an active member of the ISOQOL Digital Health Special Interest Group (SIG) and the ISPOR Translation and Cultural Adaptation (TCA) SIG.
11:45 AM — 1:00 PM
Networking Lunch
1:00 — 1:30 PM
Regulatory Affairs Round Table

Kate Porch is Director of Global Labeling within Global Regulatory Affairs at Johnson & Johnson, where she leads strategic initiatives to advance eLabeling across the organisation. She is actively engaged in shaping industry approaches to electronic product information as a member of the Inter-Association Task Force ePI Content Working Group and the EFPIA ERAO Product Information Subgroup, and as a contributor to the DIA Europe Regulatory Operations track. Kate brings over 20 years of pharmaceutical industry experience and holds a BSc (Hons) in Pharmacology from the University of Leeds, UK.

Jessica Santos is Chief Compliance & Privacy Officer at Konovo, where she leads global compliance, AI governance, data privacy, legal, and cybersecurity risk. She has over 20 years of experience in the healthcare industry, with expertise in clinical and real-world research, HEOR, medical affairs, and market research. Previously, she served at Oracle Life Sciences as Global Compliance & Quality Director and Data Protection Officer, and held leadership roles at Cerner, Kantar Health, Sermo, and TNS. She has also served as an associate professor. She holds a PhD in Social Sciences, is a Certified AI Governance Professional, serves on multiple industry boards (BHBIA, EphMRA, ISPOR, and MAPS), and is an MRS Fellow.

1:30 — 2:00 PM
The Evolving Partnership of AI and Medical Functions
Medical functions have long operated as strategic scientific partners within healthcare—shaping evidence generation, anticipating stakeholder needs, and translating complex data into actionable insights for clinical practice. While elements of responsiveness remain essential, the function has never been solely reactive. AI is now accelerating this capability, enabling Medical Affairs to operate with greater precision and foresight: identifying emerging trends, surfacing insights earlier, and delivering more personalised, context-relevant knowledge at scale. This panel brings together industry leaders to share real-world use cases from the frontlines of this evolution, and to explore what it means for human involvement as the technology advances. The bigger questions remain: how do we balance AI-driven insight with professional judgment, ethics, and empathy? And how does the role of the Medical professional continue to evolve as AI enhances—not replaces—scientific leadership? Join us as we explore the shift toward a more connected, insight-driven Medical function, and what the Medical Affairs professional of 2030 looks like in this augmented future.

Michelle Bridenbaker is the Global Head of Medical Excellence & Communications at Recordati. She also serves as Vice President-Elect of Medical Information Leaders in Europe (MILE), a pan-pharmaceutical company coalition, where she helps shape industry best practice, build future-facing technology and empower medical teams around the world. Her work supports both patients and healthcare professionals in accessing robust medical information, while enhancing educational opportunities across the European Medical Information community and beyond. She is also the co-owner and COO of Unbiased Science, a pioneering, female-led health science communications company.

Sebastian Rodriguez is a pharmacist by training, holding a degree in Pharmacy and an MSc in Pharmaceutical Medicine, with over 20 years of experience across Medical and Scientific Affairs within the pharmaceutical industry. He has held international roles across Spain, the UK, and Ireland, and brings extensive expertise in people leadership, Medical Information, and strategic Medical Affairs initiatives. Sebastian is a member of the MILE committee, where he leads Digital Innovation initiatives, and is known for strong cross-functional collaboration, clear communication and delivering high-quality, compliant outcomes for patients and healthcare professionals.

Dr Mercede Pannozzo is a Senior Medical Affairs leader with a PhD in Neuroscience and Metabolic Health and over a decade of experience delivering strategic, scientific and cross-functional impact across the pharmaceutical industry. She specialises in medical strategy, real-world evidence generation and medical innovation, with a strong track record across neuroscience, cardiometabolic health, dermatology, allergy, and women’s health. Dr Pannozzo has led national medical programmes, including Primary Care Learnings (PCL), AI-enabled diagnostics implementation, ABPI-compliant medical education, and cross-functional launch readiness. Her work sits at the intersection of medical affairs, regulatory science, data, and digital health, with a focus on transforming how organisations deliver value ethically, globally and with patients at the centre.

Alessandra Grossi is Medical Operations Director at TransPerfect UK, with over 30 years of experience in the pharmaceutical industry. She has held leadership roles in Medical Information at local, regional and global levels, as well as positions in Medical Operations, Systems and Governance at Pfizer. Alessandra has led numerous system implementations, process harmonisation initiatives and innovation programmes. She is passionate about advancing Medical Information and Communication and is committed to driving its evolution through technology adoption and innovative practices, enhancing efficiency, compliance and the overall impact of medical affairs functions globally.
2:00 — 2:15 PM
BREAK
2:15 — 3:00 PM
The State of AI in Clinical Trials: Progress, Barriers and Practical Lessons
AI is already part of clinical trial operations: in data management, automation, and increasingly, regulatory submissions. The question most organizations are wrestling with isn’t whether to adopt it, but how to do it without cutting corners on scientific integrity or compliance. This panel addresses that directly. We’ll look at what’s driving demand from sponsors, sites and patients; where AI adoption is working and where it’s breaking down; and what it takes to submit an AI-assisted package that holds up to regulatory scrutiny.

Edwin Cohen is the Owner and Principal Consultant of C&Flow, a Dutch-based consultancy specialising in strategic guidance and operational support for biotech and pharma clients. With over 20 years of experience across the full drug development spectrum, he combines deep clinical operations expertise with a strong track record of building and scaling digital health solutions within complex organisations. Previously at AstraZeneca and Evinova, Edwin led global digital transformation programmes and served as Global Business Process Owner for ICF/eConsent strategy and governance. He is also a co-host of the Digital Health Off the Record podcast.

Callum Scott is a biopharmaceutical executive with over 15 years of experience in R&D across human and animal health, specialising in vaccines and immunotherapeutics. He has led the development of novel biologics from early discovery through late-stage clinical trials and global regulatory submissions. As Senior Vice President of Development and a member of the senior leadership team at Scancell Ltd., he defines and executes development strategies, builds and leads cross-functional teams and oversees programme management, CMC and regulatory affairs. Callum holds a PhD in Molecular Microbiology, is a Chartered Fellow of the Royal Society of Biology and a member of TOPRA.

Chris Caulton leads Digital Employee Experience and Digital Workplace initiatives at Jazz Pharmaceuticals, where he helps shape how people work, connect and adopt AI in practical, human-centred ways. With deep expertise in digital transformation and enterprise technology adoption, he focuses on turning ambitious strategy into everyday impact for employees. Chris is particularly passionate about digital dexterity, AI literacy and designing workplace environments that are useful, intuitive and genuinely supportive. He brings a blend of strategic thinking, creativity and real-world delivery to conversations about the future of work, helping organisations build smarter, more connected digital cultures at scale.

Dr Hayley Holt is Director of Clinical Operations and Research Partnerships at Prima Mente, an AI biology company building biological foundation models for neurodegenerative disease. She leads clinical research programmes and international partnerships that translate AI-driven discovery into real-world impact, spanning NHS networks, global biobanks and academic and industry collaborators. Prior to joining Prima Mente, she led large-scale clinical trial operations across infectious disease, including the COVIDENCE UK study with over 20,000 participants. Her work sits at the intersection of clinical research infrastructure and biological AI, with a focus on building the data ecosystems and research frameworks that enable foundation model development at scale.

Gillian Gittens, Director of eClinical Strategy and Solutions, is a TMF industry veteran with over 25 years’ experience. Gill has a wealth of insight and expertise in managing TMF services and delivering ongoing customer success across all aspects of TMF operations. A member of the CDISC TMF Reference Model Steering Committee and Project Management Team leading the V4 initiative, Gill has key expertise and insight in industry best practice, regulatory guidance and the future of TMF management.
3:00 — 3:45 PM
Clinical Development in 2026: Challenges, Gaps and Where We Go Next
What are the biggest challenges facing clinical development right now and how prepared is the industry to meet them? In this session, attendees don’t just hear the answers, they generate them. Live polling puts the room’s collective experience on screen in real time, revealing where priorities align, where readiness gaps run deepest and where the sharpest disagreements lie. The result is a candid, peer-built snapshot of where the industry stands today and what it’s going to take to move forward.
3:45pm — 4:00 PM
Closing Remarks
4:00pm — 5:30 PM
Networking Cocktail Reception
FAQs
Is this event free?
Yes, there is no registration fee associated with this event. However, spots are limited and you will receive a confirmation email once your seat is confirmed.
Will travel and hotel be provided?
No, TransPerfect does not provide travel arrangements for C3 Summit attendees.
Who is the event for?
C3 Summit is geared toward executives, directors, and senior managers within Pharma, Medical Device, Biotech, and Contract Research Organizations. Spaces are limited and will be prioritized accordingly, therefore eligibility is subject to approval by the TransPerfect Life Sciences team.
How can I become a panelist for future C3 Summits?
Please fill out the speaker interest form below so that we can find the best speaking opportunity for you.